

PA13-115

HB6467

Commerce	402, 416, 583-584	4
House	3672-3678	7
Senate	3841-3854	14
		25

**JOINT
STANDING
COMMITTEE
HEARINGS**

**COMMERCE
PART 2
344 - 715**

2013

MICHAEL HYDE: I think -- I think we do. I think that the kind of investment that's been made here in the last couple of years is certainly causing a stir in the biomedical research world. For all of the progress that's been made in other places we're living in very difficult times as all of us know here in Connecticut.

But if you look around the country at the research institutes, hospitals and at research universities that prevailing climate of want is one of cutting back really undercutting the viability of the research and development enterprise. Connecticut is going against that trend and it has made big news around the world in the bioscience community because of the investment that's being made.

REP. LAVIELLE: Okay. Thank you very much.

MICHAEL HYDE: Thank you.

REP. PERONE: Thank you very much.

Any further questions?

Okay. Thank you.

MICHAEL HYDE: Thank you, Sir.

REP. PERONE: Okay. We're switching back to an agency. I'd like to ask Claire Leonardi followed by Wade Gibson.

CLAIRE LEONARDI: I will -- I will start with the bioscience bill. I have two other bills I want to talk on but just because Mike recently talked about this I figure we'll pick it up there. First of all good morning, Senator LeBeau, Representative Perone, Senator Frantz and Representative Lavielle and other members

8B838
HB6356
HB6467

being one of the fastest growth areas for new companies, particularly for young entrepreneurs.

We actually have invested in several social enterprises. And I think that it is a tremendous opportunity to get -- to really meet those unmet social needs without adding State dollars. And really to support a growing entrepreneurial group. So I just wanted to have my support of that. The other bill is a specific bill for CI.

It's House Bill 6467. It's an act concerning applications for financial aid from Connecticut Innovations. This bill proposes a process where we streamline the approval process for transactions of less than \$300,000 for Connecticut Innovations. During the past year we have more than doubled the number of transactions that we do at CI.

And we want to have a -- a change in the process so that we can better serve our customers and also to reduce the workload on the board of directors who approve every single transaction to enable them to focus on the more complex transactions as well as really material transactions. All of the current standards that we apply will be -- will be -- continue to be met.

And in any cattery transactions we would create a -- really strict rules as well -- as far as the processes in reporting for the board that the board would approve before we would do that. And I'd be happy to give an example so you know you know what that means. But it essentially streamline our processes for really the smallest transactions that we do.

REP. PERONE: All right. Thank you very much.



Connecticut Innovations

TESTIMONY SUBMITTED TO THE COMMERCE COMMITTEE
February 28, 2013

Claire Leonardi, CEO
Connecticut Innovations

House Bill 6467:
AA CONCERNING APPLICATIONS FOR FINANCIAL AID FROM CONNECTICUT
INNOVATIONS, INCORPORATED

Good morning Senator Lebeau, Representative Perone, Senator Frantz, Representative Lavielle and Members of the Commerce Committee. My name is Claire Leonardi and I am the Chief Executive Officer of Connecticut Innovations.

I appreciate the opportunity to testify and offer the following in support of House Bill 6467: AA CONCERNING APPLICATIONS FOR FINANCIAL AID FROM CONNECTICUT INNOVATIONS, INCORPORATED.

Connecticut Innovations (CI) has made tremendous progress with the consolidation of CI with the Connecticut Development Authority (CDA) over the past year. The current board of directors have established board committees in order to ensure that there is appropriate oversight including: Investment Committee, Loan Committee, Finance Committee, Audit Committee and Personnel Committee

Currently, all loan and investment are approved by the full Connecticut Innovations board, investment committee, or the loan committee regardless of the transaction size. CI currently works with private sector partners in an effort to leverage public dollars with private dollars and as a result, transactions are often vetted by those partners in addition to the internal due-diligence performed by CI staff.

CI would like to further develop the ability to leverage private sector dollars by streamlining the approval process for transactions with an exposure of \$300,000 or less. This change will enable CI to help expedite financial assistance for investments, loans, loan guarantees, and small business innovation grants and loans.

It is important to note that the current investment standards will be kept in place. This change is merely sought in order to reduce the workload of the board, enabling members to focus on larger more material transactions.

Connecticut Innovations, Incorporated (successor by merger to Connecticut Development Authority)

Telephone 860 258 7800

999 West Street, Rocky Hill, CT 06067

Fax 860 257 7582 (Lending)

www.ctcda.com

An Affirmative Action/Equal Opportunity Employer

Fax 860 721 9147 (Administrator)

The following oversight standards will continue to apply to all transactions:

- Transaction will be subject to appropriate internal review and in compliance with existing operating procedures.

- The investment and loan committee of the boards will provide oversight of the portfolio and transaction approved by staff

- Transaction will be subject to audits by CI's external independent public accountants and the states auditors of public accounts. The audit committee of the board has oversight responsibility for these audits.

In conclusion, CI strives to leverage its public dollars with private sector dollars in a fashion that makes the best use of states resources. As a result, the modest request will further that mission and improve access for small businesses to access CI programs in a timely and cost effective manner.

H - 1160

**CONNECTICUT
GENERAL ASSEMBLY
HOUSE**

**PROCEEDINGS
2013**

**VOL.56
PART 11
3446 - 3814**

THE CLERK:

Yes, Madam Speaker. On page 9 of today's Calendar, House Calendar 207, favorable report of the joint standing committee on Commerce, Substitute House Bill 6467, AN ACT CONCERNING APPLICATIONS FOR FINANCIAL AID FROM CONNECTICUT INNOVATIONS INCORPORATED.

DEPUTY SPEAKER MILLER:

Representative Perone.

REP. PERONE (137th):

Thank you, Madam Speaker.

I move for acceptance of the joint committee's favorable report and passage of the bill.

DEPUTY SPEAKER MILLER:

The question before the chamber is on acceptance of the joint committee's favorable report and passage of the bill.

Representative Perone, you have the floor, sir.

REP. PERONE (137th):

Thank you very much, Madam Speaker.

Under the current law, CS board of directors or board committee must approve or deny applications for financial assistants. Under the bill, the board can delegate CS staff the authority to approve

cjd/lgg/cd
HOUSE OF REPRESENTATIVES

105
May 14, 2013

applications totaling up to 150,000 per year per client. CI must still process these applications according to its written procedures.

Through you, Madam Speaker.

DEPUTY SPEAKER MILLER:

Will you remark further?

Representative Lavielle of the 143rd.

REP. LAVIELLE (143rd):

Thank you, Madam Speaker, good afternoon to you.

DEPUTY SPEAKER MILLER:

Good afternoon, madam.

REP. LAVIELLE (143rd):

I have a couple of questions for legislative intent to the proponent, if I may?

DEPUTY SPEAKER MILLER:

Will you please frame your question?

REP. LAVIELLE (143rd):

Thank you, Madam Speaker.

So, to Representative Perone, at the moment under current law, how are -- what is the structure for how deals are approved by Connecticut Innovations?

Through you, Madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Perone, will you respond, sir.

cjd/lgg/cd
HOUSE OF REPRESENTATIVES

106
May 14, 2013

REP. PERONE (137th):

Through you, Madam Speaker, the current process is that the applications are presented to the full board for approval. It basically is -- that's the main heart of the process.

Through you, Madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Lavielle, you still have the floor, madam.

REP. LAVIELLE (143rd):

Thank you, Madam Speaker.

And would that be all applications under current law?

Through you.

DEPUTY SPEAKER MILLER:

Representative Perone.

REP. PERONE (137th):

That is correct, Madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Lavielle.

REP. LAVIELLE (143rd):

Thank you, Madam Speaker.

And if I understand correctly then from now on under this bill that would still be the case, except

for any deal that involved \$150,000 or less?

Through you, Madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Perone.

REP. PERONE (137th):

Through you, Madam Speaker, that is correct. The purpose of the bill is to expedite the application process for financial assistance applications under \$150,000.

Through you, Madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Lavielle.

REP. LAVIELLE (143rd):

Thank you, Madam Speaker.

And are there any further restrictions on the \$150,000 amount?

Through you, Madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Perone.

REP. PERONE (137th):

No further restrictions. No, Madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Lavielle, you still have the floor madam.

cjd/lgg/cd
HOUSE OF REPRESENTATIVES

108
May 14, 2013

REP. LAVIELLE (143rd):

Thank you, Madam Speaker, and I thank
Representative Perone.

I do believe just for purposes of clarification
that no company is allowed to receive more than
\$150,000 under this arrangement in one year. I just
wanted to verify that that's correct.

Through you, madam Speaker.

DEPUTY SPEAKER MILLER:

Representative Perone.

REP. PERONE (137th):

Through you, Madam Speaker, yes. I would like to
thank the good representative for the clarification.
That is correct.

DEPUTY SPEAKER MILLER:

Representative Lavielle.

REP. LAVIELLE (143rd):

Thank you, Madam Speaker, and I thank the
representative for his answers.

I would concur that through the testimony by
Connecticut Innovations in our discussions in
committee that this soul intent of this bill is simply
to expedite some of the smaller transactions that

would greatly encumber the board and its deliberations and, therefore, I recommend support of the bill.

Thank you very much, Madam Speaker

DEPUTY SPEAKER MILLER:

Thank you, madam.

Will you remark further? Will you remark further?

If not, will staff and guests please come to the well of the House. Would the members please take your seats. The machine will be opened.

THE CLERK:

The House of Representatives is voting by roll.

The House of Representatives is voting by roll. Will members please return to the chamber immediately?

DEPUTY SPEAKER MILLER:

Have all members voted? Have all members voted? Will the members please check the board to determine if your vote is properly cast. If members have voted, the machine will be locked and the Clerk will take a tally.

Will the Clerk please announce the tally.

THE CLERK:

Bill Number 6467

Totally Number Voting 141

cjd/lgg/cd
HOUSE OF REPRESENTATIVES

110
May 14, 2013

Necessary for Passage	71
Those voting Yea	136
Those voting Nay	5
Those absent and not voting	9

DEPUTY SPEAKER MILLER:

The bill passes.

Will the Clerk please call Calendar Number 369.

THE CLERK:

On page 18 of today's Calendar, House Calendar 369, favorable report of the joint standing committee on Public Health, Senate Bill 63, AN ACT CONCERNING GRANTS WITH THE BIOMEDICAL RESEARCH TRUST FUND FOR STROKE RESEARCH.

DEPUTY SPEAKER MILLER:

Representative Johnson.

The Chamber will stand at ease.

(Chamber at ease.)

DEPUTY SPEAKER MILLER:

Representative Aresimowicz.

REP. ARESIMOWICZ (30th):

Yes, Madam Speaker, I move that we pass this bill temporarily.

S - 664

**CONNECTICUT
GENERAL ASSEMBLY
SENATE**

**PROCEEDINGS
2013**

**VOL. 56
PART 13
3813 - 4129**

Senator LeBeau.

SENATOR LEBEAU:

Thank you, Madam President.

Thank you, Senator Frantz. I guess that's technical leadership.

If there's no objection, I would like to move this bill to the Consent Calendar.

THE CHAIR:

Seeing no objection, so ordered.

Mr. Clerk.

THE CLERK:

On Page 24, Calendar 600, Substitute for House Bill Number 6467, AN ACT CONCERNING APPLICATIONS FOR FINANCIAL AID FROM CONNECTICUT INNOVATIONS, INCORPORATED, Favorable Report of the Committee on COMMERCE.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Madam President, again, thank you.

I move acceptance of the Joint Committee's Favorable Report and passage of the bill.

THE CHAIR:

The motion is on passage and -- and -- I'm sorry, acceptance and passage.

Will you remark, sir?

SENATOR LEBEAU:

Yes, Madam President.

I've got my cup of coffee right here. And if you would like me to get you one, I would be happy to do so.

THE CHAIR:

No, I think I'll be fine. Thank you.

SENATOR LEBEAU:

This bill authorizes -- it's not as technical. This bill authorizes Connecticut Innovations governing board, under certain conditions, to delegate to the CI Staff it's duty to approve or deny applications for loans, loan guarantees, equity investment, and other forms of economic development assistance.

The board -- essentially, the board may delegate this duty for applications for requesting no more than \$150,000. What -- what -- what has happened is, as this legislature has increased the number of dollars going to CI over the last couple of years, \$25 million a year, I believe, for five years. And as a result, there's a lot more activity. And in the past, the -- the CI Board had to approve every single application and the entire board sitting together had to approve every single application for any kind of assistance that they -- that they would give. So this become very cumbersome.

And what we worked out, the Committee this year worked out an agreement that we thought that this was a fair way to -- to proceed that would be both efficient and yet still maintain oversight by the board and the -- and this, in a sense, the civilians who serve on the board to ensure that the -- that we move ahead and we have sufficient oversight and sufficient accountability and at the same time be able to move many of these applications that in a much more -- in a much more expeditious fashion.

So that is why this proposal is front -- in front of us today. That's why this bill is in front of us. And it has had a lot of support through the building and through our Committees.

Thank you, Madam President.

THE CHAIR:

Thank you.

Will you remark?

Senator Frantz.

SENATOR FRANTZ:

Thank you, Madam President.

I stand in favor of the bill. I want to thank Senator LeBeau for being a great person to work with on this. It was pretty heavily negotiated in Committee and at first the (inaudible) seemed to be inordinately high and unreasonable, but you have been very reasonable in the negotiation process, both overtly and also when we -- when we were offline. So thank you for that. I think the -- the Committee Members fully understood the implications here.

It -- it is -- it's -- it's an unusual animal, now that CI has merged with CDA. You have essentially a bank -- traditional bank function mixed in with a private equity/venture capital group, which is a very, very different set of talents, expertise, and backgrounds, and, frankly, mindsets. So I -- I worried at first in seeing the -- the high level of limits under which they could allow just staff and -- and existing management to make these decisions, without the approval of the Investment Loan Committee or the entire Board. So that's how we got into the discussions and how we ended up here.

I do feel comfortable and -- and I'll tell you why, with the \$150,000, and importantly, that's once per year. You can't do this like every other day, get a 150,000 dollar infusion of equity or capital of some sort. But I'll tell you why I feel comfortable. It's because you've got a great staff there. You have a great board of 17 people who are keeping a real close eye on staff. Making sure that we have the best and

the brightest available to CI. And that's step number one.

Step number two is that the staff and the local management is very, very high quality. They -- they do know what they're doing, whether you're talking about straight equity investments or various hybrids of the different kinds of equity investments you can make in a younger company, all the way down to traditional lending and, in the case of CI, and in many cases it the lender of last resort, which is a specialty item. We've got some real good competence there as well.

So after our long discussion at the Committee and knowing the group down there quite well because I used to be heavily involved with CDA anyway and CI to a certain degree and some of the Board Members down there. I have a lot of confidence that this will work out.

And I thank Senator LeBeau again.

Thank you, Madam President.

THE CHAIR:

Thank you.

Will you remark? Will you remark?

Senator McKinney.

SENATOR MCKINNEY:

Thank you, Madam President.

Madam President, if I could, a few questions through you to Senator LeBeau.

THE CHAIR:

Please proceed, sir.

SENATOR MCKINNEY:

First let me -- let me state by saying that in our Caucus, Senator Frantz very capably represented how the two of you work very well together to modify what was a much more generous ask on behalf CI, Connecticut Innovations. So I think this is better than what they had originally asked for. I -- I have to admit before asking you questions, I'm not comfortable though.

And so if I could, through you, Madam President.

Under current law, can -- can staff give out any amount of financial assistance without board approval?

Through you, Madam President.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Through you, Madam President.

I do not believe so.

THE CHAIR:

Senator McKinney.

SENATOR MCKINNEY:

Thank you.

And through you, Madam President.

Are -- are staff at Connecticut Innovations, and I -- I don't -- let me just say I don't -- I don't know if I know any of the staff at Connecticut Innovations. I certainly don't have anything bad to say about any of them. Those that I've met over the years have been -- have done an excellent job, but are they subject to the same ethical standards, ethics rules that we are as State employees?

Through you, Madam President.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Through you, Madam President.

I believe so. I think I remember discussing that.

Through you, Madam President.

I believe three or four years ago that this issue came in front of the Senate and we discussed it at that time. So I'm pulling on that memory of -- of that to say yes, they -- they are subject to the same ethical considerations that we are.

THE CHAIR:

Senator McKinney.

SENATOR MCKINNEY:

Thank you, Madam President.

And -- and through you, Madam President.

Senator LeBeau, do you know, and -- and I don't and -- and I'm not going to press you if you don't. I'll find out an answer, but are staff at Connecticut Innovations covered under any revolving door-type of legislation in that they may be prohibited upon leaving Connecticut Innovations, from getting a certain job within a period of time thereafter?

Through you, Madam President.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Through you, Madam President.

I am not sure of that answer, Senator. I -- I know some staff are. The higher-level staff. I'm not sure

about the members of the lower level staff. I know like Tony Roberto and others cannot just move on and go on -- go into private investments without having a certain time period before -- that -- that they have to remain -- in a sense, inactive.

SENATOR MCKINNEY:

And --

THE CHAIR:

Senator.

SENATOR MCKINNEY:

Thank you.

And -- and through you, Madam President.

Are the -- the bill authorizes the board under, again, under certain circumstances to delegate to the staff the duty to approve or deny of applications for loans, loan guarantees, equity investments, and -- and other economic development assistance under \$150,000. Does this limit the board's delegation only to those higher-level staff? And I -- I want to be clear. I'm not asking what you think they'll do, because -- but can they delegate it to any member of the CI staff, I guess, under the language of the bill?

Through you, Madam President.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Through you, Madam President.

I believe under the -- under the language of the bill, that normally the process is still a team -- a team approach to recommendations that are made. And I believe that staff, as a group, make the recommendation.

Through you, Madam President.

I would like to try to make you feel more comfortable, Senator. And if -- if you don't -- would not mind I have some additional data I would like to present.

SENATOR MCKINNEY:

That's fine. If you can -- if you can answer my questions before I ask them, that's even better.

SENATOR LEBEAU:

Okay. Well let's -- let me -- let me take a look at some history and -- because I've -- I've asked, because I had some questions myself about how this would roll out. So I asked the CI -- I asked the folks to put together some data regarding the recent history, in terms of loans and grants, et cetera that have -- have occurred. Under the Technology Talent Bridge and Small Business Innovation and Diversification Grant Program, in 2012 there were 19 companies that were less than -- less than 150,000 for a total of 373,000.

That's -- that's an -- and I'm going to give you this data, Senator, it's going to -- you're going to see that almost all of the companies in almost all the cases that are under 150,000, they're really around 20,000. So the average there is a -- is a 20,000.

The same -- the same is true in the year 2013. Fiscal year 2013, so far there were 22 companies that have gotten 372,000. So again, is less than 20,000, about \$18,000 a -- a company.

In Venture Capital in 2012, there were 24 companies below 150,000, totaling three million. Now that's a higher amount but there were 30, 70 -- 37 companies above 150,000, totaling 27 million.

So here's -- here's my point, Senator. And I could go down through the other companies and it's going to be the same reflect -- reflect the same thing. Ninety percent -- 90 percent of the dollars given out by CI were above \$150,000. And they were the much larger amounts. So when -- in terms of using our staff

effectively and in terms of having our volunteers come in who serve on the board and asking them to come in to approve these allocations, that we're doing this effectively going forward because we're going to ask them to be dealing with a more substantial tranches of dollars that we're giving out. And that's similar in the year 2013, where nine companies total 1.1 million, below 150,000. Eighteen companies totaled almost 9 million. So again, 90 percent of the dollars were below -- excuse me, were above \$150,000.

And in -- and for loans 100 percent of all the loans totaling 17 million in 2012, were -- were over 150,000. And for 2013, also 100 percent of the loans totaling almost \$6.3 million were above 150,000. So those larger amounts, that's where most of the dollars are going and it's -- it -- they will be covered. So we're looking at the smaller amounts to try to move this -- move these smaller amounts along a little more quickly and to help these smaller companies, particularly smaller companies when they're looking for dollars to get it to them expeditiously with -- after a professional review by the members of the staff.

THE CHAIR:

Senator McKinney.

SENATOR MCKINNEY:

Thank you.

Actually, that is very helpful. And I -- I'm not going to try to make a big deal out of this. I mean, these are public dollars and we know that. And we have -- I -- I don't need to -- I've done it in the past, I'll probably do it before next Wednesday. Get into the Manufacturing Assistance Act dollars and things of that nature. But these are -- this is taxpayer money that I would certainly argue, and I -- I know you would agreed, because you've helped do a lot of it, that is very well utilized by Connecticut Innovations. But it's still taxpayer dollars. And so I -- as I -- as I hear the numbers with the loans, the average seem to be about \$20,000 a loan for 19 companies. Kind of begs the question, why 150,000-

dollar max. Yet for the Venture Capital, the average there seemed to be about 124,000. If -- if we can have -- I don't believe CI currently requires the 17-member board to vote and approve everything. I think they can have -- maybe I -- maybe I should make sure that's a question.

Madam President, through you.

Is it true that the board doesn't have to vote as a 17-member board. They can have a committee of the board vote to approve of certain projects currently. Is that correct?

Through you, Madam President.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Through you, Madam President.

I am not absolutely sure, but I believe that there's a quorum of the board that is necessary for the -- currently for the approval of any dollars.

SENATOR MCKINNEY:

Thank you.

THE CHAIR:

Senator McKinney.

SENATOR MCKINNEY:

Thank you.

Then -- then I guess, did -- did you consider and -- and -- and if so why did you decide it wasn't the right way to go that with amounts below a certain number, here \$150,000, that some board member involvement would be required? Maybe a subcommittee, maybe a smaller number, maybe three board members, instead of just solely giving staff the discretion?

Through you, Madam President.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Through you, Madam President.

To be honest, we did not consider that. We thought it would be a -- a little difficult and who those board members might be. It's -- it's almost always difficult to figure out how to do these things if you're not going to kind of have the whole board be part of the --

SENATOR MCKINNEY:

Thank you.

SENATOR LEBEAU:

I could see -- I could see where questions would be raised, Senator, about why'd you call up this person and why did this person come in or, you know, I could see some difficulties with trying to make that work in a real sense.

THE CHAIR:

Senator McKinney.

SENATOR MCKINNEY:

Thank you.

And I -- I -- I understand that. I could also see establishing a, say three-member subcommittee of the board that would deal with Venture Capital requests under \$150,000 and another three-member committee set up to deal with loan requests under \$150,000. Did you consider and -- and -- and if so, why did you decide not to change roles or responsibilities or reviews of staff members that would now be making decisions?

Let me -- let me just step back a little bit. Did you -- did you think about limiting who on staff could make the decisions? Would it be just the CEO? Because I'm not sure if the CEO has legislative approval or not, but did you consider limiting who on CI could make the final decision of staff?

Through you, Madam President.

THE CHAIR:

Senator LeBeau.

SENATOR LEBEAU:

Through you, Madam President.

Not specifically.

THE CHAIR:

Senator McKinney.

SENATOR MCKINNEY:

Thank you.

Madam President, I think that's all the questions I have.

I want to thank Senator LeBeau for answering my questions.

I heard everything that Senator LeBeau said. I thank him for answering my questions. I've talked to Senator Frantz. He was a strong advocate in our Caucus for this. I don't -- I don't know if we should be allowing staff to make the decision to give Equity Investments or other Development -- Economic Development Assistance of up to \$150,000 without board review. If we're going to have staff, I think we should know who on staff is going to do it, have it limited to the highest level of staff. I would want some legislative oversight perhaps of who that staff personnel is.

And I -- and I don't -- I want to be very cautious in how I say this, but a lot of people have done a lot of dumb things for \$15,000, much less \$150,000. A lot of these companies who get Economic Assistance could -- could turn out to be hugely financially successful companies. And yet, I don't know as I sit here, whether or not a staff member who may sit on that decision to give a venture capitalist \$125,000, which could be the difference between that venture capitalist succeeding or failing, which -- which could lead that venture capitalist not to \$150,000, but to tens of millions of dollars. And then one day, surprisingly not coincidentally or just by sheer luck, end up hiring that staff person.

I don't know that we have any of those protections. And so it is not -- it is not farfetched and I don't think it's disparaging to the current employees to say that it's possible someone could make a decision whether or not to give \$150,000 of taxpayer money out as a staff level decision, because it may in some way (inaudible) to their financial benefit in the future. It's happened all over the place. And I think we need to have protections in here that aren't in here.

So normally I would probably go on longer, Madam President, but I -- I would -- since this is a House bill, this is final passage, which frustrates me. I would hope maybe next session I might be able to sit down with the leadership of the Commerce Committee and offer some ideas to -- to put in some protections, but as of right now, I am just not comfortable allowing the decision to give away that amount of money to be made by anyone other than the board. And for that reason, will vote no.

THE CHAIR:

Thank you.

Will you remark further? Will you remark further?

If not, Mr. Clerk will you call for a roll call vote and the machine will be open.

THE CLERK:

Immediate roll call has been ordered in the Senate.
Senators please return to the Chamber. Immediate roll
call has been ordered in the Senate.

THE CHAIR:

Members please stay close to the Chamber. We'll be
voting right after this again.

If all members have voted, if all members have voted,
the machine will be closed.

Mr. Clerk will you please call the tally.

THE CLERK:

House Bill 6467

Total Number Voting	34
Necessary for Adoption	18
Those voting Yea	27
Those voting Nay	7
Those absent and not voting	2

THE CHAIR:

Bill passes.

Senator Looney.

SENATOR LOONEY:

Thank you, Madam President.

Madam President, I believe the Clerk is now in
possession of Senate Agenda Number 2 for today's
Session.

THE CHAIR:

Mr. Clerk.

THE CLERK:

Clerk is in possession of Senate Agenda Number 2.
It's dated Thursday, May 30, 2013. It's been copied
and it's on Senators' desks.